FDCDDQ
VERV

Federation des caisses Desjardins du Quebec’s Verve Therapeutics VERV Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,700
Closed -$7.77K – 2840
2025
Q1 		$7.77K Hold
1,700
– – ﹤0.01% 2037
2024
Q4 		$9.59K Hold
1,700
– – ﹤0.01% 1897
2024
Q3 		$8.23K Hold
1,700
– – ﹤0.01% 1953
2024
Q2 		$8.3K Buy
+1,700
New +$10.7K ﹤0.01% 1852

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's VERV Position: Q2 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 1,700 shares — an estimated $7.77K sold.

Federation des caisses Desjardins du Quebec first reported a position in VERV in Q2 2024 and held it in 4 quarters. The position peaked at $9.59K in Q4 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Federation des caisses Desjardins du Quebec reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 1,700 Verve Therapeutics shares in Q2 2025, an estimated $7.77K.
  • Federation des caisses Desjardins du Quebec first reported a position in Verve Therapeutics in Q2 2024 and held it in 4 quarters.
  • Federation des caisses Desjardins du Quebec's Verve Therapeutics position peaked at $9.59K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2025, filed 14 Aug 2025.